Black Diamond Therapeutics (BDTX) Accounts Payables (2018 - 2026)
Black Diamond Therapeutics' (BDTX) quarterly Accounts Payables came in at $3.0 million in Q1 2026, up 12.98% YoY from $2.6 million in Q1 2025, and up 412.78% on a QoQ basis from $579000.0 in Q4 2025.
Black Diamond Therapeutics (BDTX) Accounts Payables (2018 - 2026) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 9 years of Accounts Payables data on file, last reported at $3.0 million in Q1 2026.
- Quarterly Accounts Payables rose 12.98% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.0 million (up 12.98% YoY) and the FY2025 annual result came in at $579000.0, down 85.55% from the prior year.
- Accounts Payables rose to $3.0 million in Q1 2026, from $579000.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $5.8 million in Q3 2022 to a low of $579000.0 in Q4 2025.
- A 5-year average of $2.1 million and a median of $2.0 million in 2024 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2023 — Accounts Payables sank 87.95% — and 2024, when it surged 184.01%.
- Tracing BDTX's Accounts Payables over 5 years: stood at $1.9 million in 2022, then advanced by 23.81% to $2.3 million in 2023, then jumped by 72.42% to $4.0 million in 2024, then sank by 85.55% to $579000.0 in 2025, then soared by 412.78% to $3.0 million in 2026.
- The last three Accounts Payables figures came in at $3.0 million (Q1 2026), $579000.0 (Q4 2025), and $975000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Black Diamond Therapeutics | 125.92 Mn | 15.42 Mn | - | 1.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.40 Mn |
| Mar 31, 2026 | 2.97 Mn |
| Dec 31, 2025 | 579,000.00 |
| Sep 30, 2025 | 975,000.00 |
| Jun 30, 2025 | 771,000.00 |
| Mar 31, 2025 | 2.63 Mn |
| Dec 31, 2024 | 4.01 Mn |
| Sep 30, 2024 | 1.97 Mn |
| Jun 30, 2024 | 763,000.00 |
| Mar 31, 2024 | 1.18 Mn |
| Dec 31, 2023 | 2.32 Mn |
| Sep 30, 2023 | 694,000.00 |
| Jun 30, 2023 | 2.74 Mn |
| Mar 31, 2023 | 3.05 Mn |
| Dec 31, 2022 | 1.88 Mn |
| Sep 30, 2022 | 5.76 Mn |
| Jun 30, 2022 | 2.22 Mn |
| Mar 31, 2022 | 1.88 Mn |
| Dec 31, 2021 | 4.11 Mn |
| Sep 30, 2021 | 4.86 Mn |